Company press releases

Displaying 1 - 50 of 69 results
Released Company Title Industry Topic
19 Nov 2025
07:46 CET 		HYLORIS Hyloris Board of Directors appoints Stijn Van Rompay as CEO 20103010 Biotechnology Corporate life
14 Nov 2025
07:38 CET 		HYLORIS Hyloris Announces Positive Clinical Study Results for IV Aspirin 20103010 Biotechnology Corporate life
28 Oct 2025
07:01 CET 		HYLORIS Hyloris and Orion Partner to Bring Tranexamic Acid RTU to Key European Markets 20103010 Biotechnology Corporate life
27 Oct 2025
07:06 CET 		HYLORIS Hyloris Announces Partnership with Grand Life Sciences Group for HY-094 in China 20103010 Biotechnology Corporate life
25 Sep 2025
07:06 CEST 		HYLORIS Consolidated 2025 Half-Year Results and Outlook: Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position 20103010 Biotechnology Corporate life
17 Jul 2025
12:03 CEST 		HYLORIS Hyloris Announces Positive Clinical Study Results for Atomoxetine Oral Solution 20103010 Biotechnology Corporate life
23 Jun 2025
07:03 CEST 		HYLORIS Hyloris Partners with Kuvatris Therapeutics to Advance Suramin IV Development for Sleeping Sickness, Targeting a Priority Review Voucher 20103010 Biotechnology Corporate life
03 Jun 2025
17:58 CEST 		HYLORIS Hyloris Announces U.S. FDA Approval for Tranexamic Acid Ready-to-Use (RTU) 20103010 Biotechnology Corporate life
22 May 2025
07:18 CEST 		HYLORIS Hyloris Announces License Deal with AFT Pharmaceuticals for XTRAZA™ 20103010 Biotechnology News contracts
13 May 2025
07:00 CEST 		HYLORIS Hyloris Announces Partnerships for Valacyclovir Oral Suspension Covering Canada, Australia, New Zealand and the Netherlands 20103010 Biotechnology News contracts
01 May 2025
00:21 CEST 		HYLORIS Hyloris releases Annual Report 2024 20103010 Biotechnology Corporate life
31 Mar 2025
07:00 CEST 		HYLORIS Hyloris Announces a New Product Candidate Targeting Iron Deficiency 20103010 Biotechnology Other subject
20 Mar 2025
18:00 CET 		HYLORIS Hyloris Pharmaceuticals Reports 2024 Results and Provides Business Outlook 20103010 Biotechnology Commercial results
19 Mar 2025
18:02 CET 		HYLORIS Hyloris Announces Positive IDMC Recommendation to Continue Alenura® Study Following Interim Assessment 20103010 Biotechnology Other subject
16 Mar 2025
15:36 CET 		HYLORIS Hyloris Broadens Pipeline with Ready-To-Use Pantoprazole IV 20103010 Biotechnology Other subject
13 Mar 2025
18:31 CET 		HYLORIS Hyloris Announces Positive Study Results for Dofetilide IV 20103010 Biotechnology Other subject
25 Feb 2025
07:18 CET 		HYLORIS Hyloris Announces FDA Acceptance of New Drug Application (NDA) for Valacyclovir Oral Liquid 20103010 Biotechnology Other subject
25 Feb 2025
07:01 CET 		HYLORIS Hyloris Broadens Pipeline with RedHill’s Ondansetron Extended-Release 20103010 Biotechnology News contracts
03 Feb 2025
07:13 CET 		HYLORIS Hyloris Announces Partnership with Colonis Pharma for XTRAZA in the UK 20103010 Biotechnology News contracts
31 Jan 2025
18:01 CET 		HYLORIS Information on Voting Rights and Denominator 20103010 Biotechnology Other subject
22 Jan 2025
17:59 CET 		HYLORIS Information on Voting Rights and Denominator 20103010 Biotechnology Other subject
09 Jan 2025
20:07 CET 		HYLORIS Information on Voting Rights and Denominator 20103010 Biotechnology Other subject
30 Dec 2024
18:40 CET 		HYLORIS Hyloris Announces Positive Study Results for Valacyclovir Oral Suspension for European Markets 20103010 Biotechnology Other subject
14 Mar 2024
07:00 CET 		HYLORIS Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives 20103010 Biotechnology Income
14 Mar 2024
07:00 CET 		HYLORIS Hyloris Reports Full Year Results for 2023 & Provides Business Outlook 20103010 Biotechnology Income
14 Mar 2024
06:59 CET 		HYLORIS Communiqué à la requête de la FSMA sur les transactions avec QliniQ 20103010 Biotechnology Other financial transaction
14 Mar 2024
06:59 CET 		HYLORIS Communication at the request of the FSMA on the transactions with Qliniq 20103010 Biotechnology Other financial transaction
08 Mar 2024
07:00 CET 		HYLORIS Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024 20103010 Biotechnology Commercial results
08 Mar 2024
07:00 CET 		HYLORIS Hyloris to Report 2023 Full-Year Results on 14 March 2024 20103010 Biotechnology Commercial results
27 Feb 2024
18:00 CET 		HYLORIS Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada 20103010 Biotechnology Commercial operations
27 Feb 2024
18:00 CET 		HYLORIS Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au Canada 20103010 Biotechnology Commercial operations
14 Feb 2024
18:00 CET 		HYLORIS Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions Dentaires 20103010 Biotechnology Other subject
14 Feb 2024
18:00 CET 		HYLORIS Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures 20103010 Biotechnology Other subject
30 Jan 2024
07:00 CET 		HYLORIS Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) 20103010 Biotechnology Commercial results
30 Jan 2024
07:00 CET 		HYLORIS Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV) 20103010 Biotechnology Commercial results
18 Jan 2024
19:00 CET 		HYLORIS Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) 20103010 Biotechnology Products and services
18 Jan 2024
19:00 CET 		HYLORIS Hyloris Elargit son Portefeuille de Produits avec un Nouveau Produit Candidat pour le Lichen Scléreux Vulvaire (LSV) 20103010 Biotechnology Products and services
16 Jan 2024
19:30 CET 		HYLORIS Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) 20103010 Biotechnology Products and services
16 Jan 2024
19:30 CET 		HYLORIS La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA) 20103010 Biotechnology Products and services
26 Dec 2023
18:00 CET 		HYLORIS Hyloris Annonce des Résultats Cliniques Positifs pour son Produit Valacyclovir (HY-029) en suspension orale 20103010 Biotechnology Products and services
26 Dec 2023
18:00 CET 		HYLORIS Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029) 20103010 Biotechnology Products and services
21 Dec 2023
18:30 CET 		HYLORIS Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome 20103010 Biotechnology Alliances and agreements
21 Dec 2023
18:30 CET 		HYLORIS Hyloris élargit son Portefeuille avec un Nouveau Produit Candidat pour le Syndrome de la Bouche Brûlante 20103010 Biotechnology Alliances and agreements
04 Dec 2023
07:00 CET 		HYLORIS Hyloris annonce l'approbation du Gel Podofilox par la FDA américaine 20103010 Biotechnology Commercial results
04 Dec 2023
07:00 CET 		HYLORIS Hyloris announces US FDA approval for Podofilox Gel 20103010 Biotechnology Commercial results
24 Oct 2023
07:00 CEST 		HYLORIS Hyloris annonce un accord de licence pour l'Atomoxetine Oral Liquide au Canada 20103010 Biotechnology Commercial operations
24 Oct 2023
07:00 CEST 		HYLORIS Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada 20103010 Biotechnology Commercial operations
18 Oct 2023
07:00 CEST 		HYLORIS Hyloris announces U.S. FDA Approval of Maxigesic® IV 20103010 Biotechnology Commercial operations
18 Oct 2023
07:00 CEST 		HYLORIS Hyloris annonce l’approbation de Maxigesic® IV par la FDA Américaine 20103010 Biotechnology Commercial operations
06 Sep 2023
22:00 CEST 		HYLORIS Hyloris Pharmaceuticals présente ses résultats semestriels pour 2023 et ses perspectives d'activité 20103010 Biotechnology Commercial results